Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01597310 · ClinicalTrials.gov registry record · Phase 1
Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study
A Phase 1 study, sponsored by Knopp Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01597310 is a Phase 1 study that has completed, run by Knopp Biosciences. The registered enrollment target is 15 participants.
The verdict
NCT01597310, a Phase 1 study, has completed, sponsored by Knopp Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will assess the effect of dexpramipexole on the pharmacokinetics (PK) of the CYP2C9 probe substrate warfarin in healthy volunteers.
Interventions
- DRUG Warfarin
- DRUG Dexpramipexole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01597310
The ClinicalTrials.gov registry entry for NCT01597310 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Knopp Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT01597310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01597310 about?
NCT01597310 is a clinical study titled "Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study". This study will assess the effect of dexpramipexole on the pharmacokinetics (PK) of the CYP2C9 probe substrate warfarin in healthy volunteers.
What is the current status of trial NCT01597310?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2012-05. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01597310?
The interventions under investigation include: Warfarin (DRUG), Dexpramipexole (DRUG).
Who is sponsoring clinical trial NCT01597310?
This trial is sponsored by Knopp Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.